{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:28:51Z","timestamp":1777868931134,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,11,27]],"date-time":"2009-11-27T00:00:00Z","timestamp":1259280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,11,27]],"date-time":"2009-11-27T00:00:00Z","timestamp":1259280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fetal Diagn Ther"],"abstract":"<jats:p>The development of multiple-marker biochemical screening has increased the percentage of aneuploidies detected for all age groups and has also increased the abnormality\/amniocentesis ratio from about 1 in 85 for maternal serum \u03b1-fetoprotein alone (single screening) to about 1 in 50 for either maternal serum \u03b1-fetoprotein plus human chorionic gonadotropin (double screening) or maternal serum \u03b1-fetoprotein combined with human chorionic gonadotropin and unconjugated estriol (triple screening). We evaluated the decisions to have or decline amniocentesis of 985 patients \u2018at risk\u2019 by either single, double, or triple screening, as multiple markers were phased in over a 3-year period. The patient acceptance of the procedure did not change (approximately 80%) either by actual risk or type of biochemical screening. The labeling of \u2018at risk\u2019 status is more important than actual numerical risks, and the patient perception of risk status must be considered in counseling.<\/jats:p>","DOI":"10.1159\/000264245","type":"journal-article","created":{"date-parts":[[2009,11,30]],"date-time":"2009-11-30T03:50:28Z","timestamp":1259553028000},"page":"286-289","source":"Crossref","is-referenced-by-count":2,"title":["Impact of Abnormal Second-Trimester Maternal Serum Single, Double, and Triple Screening on Patient Choices about Prenatal Diagnosis"],"prefix":"10.1159","author":[{"given":"Donna L.B.","family":"Lowry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie A.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric L.","family":"Krivchenia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaina","family":"Dvorin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"Duquette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark I.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,11,27]]},"container-title":["Fetal Diagnosis and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000264245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:53:30Z","timestamp":1777553610000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000264245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,27]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000264245","archive":["Portico"],"relation":{},"ISSN":["1015-3837","1421-9964"],"issn-type":[{"value":"1015-3837","type":"print"},{"value":"1421-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,27]]}}}